Bli medlem
Bli medlem

Du är här


Oncology Venture A/S: Oncology Venture is streamlining its communications by publishing press releases in English only goin...

Pres Release

Hørsholm, November 12, 2019 ? Oncology Venture A/S (?Oncology Venture?)
today announces that the company has chosen to streamline its
communications by publishing press releases in English only going forward.

For further information, please contact:


Henrik Moltke, CFO
Telephone +45 53 63 96 37  

About Oncology Venture A/S
Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST)
develops drugs for personalized treatment of cancer guided by its
proprietary drug response predictor technology, DRP®. The company has a
mature portfolio of seven drug candidates, including compounds in the
pre-registration stage.
The product portfolio includes: 2X-121 a PARP inhibitor in Phase 2 for
Ovarian cancer; Dovitinib, for Renal Cell Carcinoma. Ixabepilone for the
treatment of breast cancer. LiPlaCis®, a liposomal formulation of cisplatin
in Phase 2 trial for breast and prostate cancer 2X-111, a liposomal
formulation of doxorubicin under manufacturing for Phase 2 in breast
cancer; irofulven, in Phase 2 for prostate cancer; and APO010, an
immuno-oncology product in Phase 1/2 for multiple myeloma.

About the Drug Response Predictor ? DRP® Companion Diagnostic
Oncology Venture uses its multi gene DRP® to select those patients who by
the genetic signature of their cancer are found to have a high likelihood
of responding to the drug. By screening patients before treatment, the
response rate can be significantly increased. The DRP® method builds on the
comparison of sensitive vs. resistant human cancer cell lines, including
genomic information from cell lines combined with clinical tumor biology.
DRP® is based on messenger RNA from the patient?s biopsies.
DRP® has proven its ability to provide a statistically significant
prediction of the clinical outcome from drug treatment in cancer patients
in 29 out of 37 clinical studies that were examined.
The DRP® platform can be used in all cancer types and is patented for more
than 70 anti-cancer drugs in the US.

Follow us on social media:

Learn more at


Certified Adviser:
Svensk Kapitalmarknadsgranskning AB, Email: Tel: +46 11 32 30

This information is information that Oncology Venture A/S is obliged to
make public pursuant to the EU Market Abuse Regulation. The information was
submitted for publication on November 12. 2019.


* Oncology Venture will streamline its communications by publishing
press releases in English only

Författare Hugin Nyheter

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.